Janssen springhouse: Access to this page has been denied.

Опубликовано: December 9, 2022 в 4:34 pm

Автор:

Категории: Miscellaneous

Articles with Janssen Research & Development





At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients’ suffering, and solve the most important unmet medical needs of our time.
As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:
• cardiovascular and metabolism,
• immunology,
• infectious diseases and vaccines,
• neuroscience, and
• oncology.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.
We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Website: http://www.janssenrnd.com/our-company
Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research.
The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.
http://www.janssenlabs.com/about/overview






  • BioSpace spoke with Janssen’s Fiona Elwood about the company’s myasthenia gravis candidate nipocalimab, which is currently recruiting for two Phase III trials.






  • XBiotech Inc. announced that it executed Manufacturing Agreement with Janssen Research & Development, LLC to manufacture clinical product, including Bermekimab, a True Human monoclonal antibody sold to Janssen by XBiotech in December 2019.







  • Janssen Research & Development to employ Total Brain data for new insights into depression.







  • Persephone Biosciences Inc. today announced a collaboration with Janssen Research & Development, LLC, (Janssen) for the colorectal cancer (CRC) arm of Persephone’s ARGONAUT study.  







  • OrigiMed Co., Ltd. (“OrigiMed”) announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. (“Janssen”).




  • org/Article”>




    Although vaccines and effective therapeutics are powerful tools in preventing and treating COVID-19, we’re not done battling the disease just yet. For those stories and more, read on.








  • AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.








  • Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant. Read on for more information.








  • It was based on data from the APOLLO trial showing the drug significantly decreased the risk of progression or death by 37% compared to dexamethasone alone. 








  • ​Janssen presented the Phase III Glow study for the elderly with CLL or SLL and the overall survival results from the Phase III MAIA study for patients with NDMM. 








  • Shares of Protagonist Therapeutics climbed nearly 4% in premarket trading after the company announced its lead drug candidate rusfertide snagged Breakthrough Therapy Designation from the U. S. FDA.







  • IQVIA™ (NYSE: IQV) announces that since September 2020 it has been collaborating with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on the Phase 3 COVID-19 vaccine clinical trials.

    The studies leverage IQVIA’s suite of decentralized trial solutions that support both on-site and remote study delivery through a mix of tel







  • — Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster —




  • 12/2/2020

    MorphoSys AG announced that its licensee Janssen Research & Development, LLC. reported the European Commission’s approval for the use of Tremfya in the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug therapy.







  • Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a strategic collaboration with Janssen Research & Development, LLC (Janssen), in which Tempus will work closely with Janssen data scientists and oncologists focused on oncology clinical development programs. The collaboration is part of a multi-year data agreement, which is facilitating predictive AI/machine learning projects, as well as







  • Research alliance will leverage advanced data analytics and genomic testing to improve recruitment of patients in oncology clinical trials







  • GeneCentric Therapeutics today announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC). The research will involve the application of GeneCentric’s advanced RNA-based molecular profiling platform to elucidate poten







  • The Industrial Macromolecular Crystallography Association, an association of pharmaceutical companies that leverages the power of high-energy X-rays to accelerate structural biology research for drug discovery, announced that Janssen Research & Development, LLC has joined IMCA.







  • IMMUNOPRECISE ANTIBODIES LTD., a global leader in therapeutic antibody discovery and development, announced that it, through its subsidiary Talem Therapeutics, has entered into a research license agreement with Janssen Research & Development, LLC, providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target.







  • An oral, gut-restricted IL-23 receptor antagonist peptide is successfully nominated as a second-generation development candidate, advancing the collaboration and triggering a $5M milestone payment




  • First




  • 1


  • 2


  • 3





  • Next